BeOne Medicines Ltd. (ONC) company profile
Close on Nov 16, 2026Market cap $46.76BP/E 73.6Yield –
About BeOne Medicines
Pharmaceutical Preparations, SIC 2834
BeOne is a global biopharmaceutical organization focused on discovering, developing, and commercializing treatments for cancer patients worldwide. The enterprise concentrates its clinical pipelines and commercial activities primarily on hematology and solid tumor oncology. Its commercialized portfolio includes internally developed therapies such as the Bruton's tyrosine kinase inhibitor BRUKINSA, the anti-PD-1 monoclonal antibody TEVIMBRA, the B-cell lymphoma 2 inhibitor sonrotoclax, and the PARP inhibitor PARTRUVIX, alongside various in-licensed therapies covering diverse hematologic and solid malignancies. Its customer base consists of healthcare systems, hospitals, and cancer patients accessing therapies through public and private healthcare reimbursement frameworks.
The company operates on an international scale, marketing and commercializing products across more than 60 countries and regions, including extensive availability of core treatments in over 75 markets globally. BeOne maintains clinical operations across six continents supported by internal development and manufacturing infrastructure, with primary operational subsidiaries situated in the United States, China, the United Kingdom, and Australia. The enterprise is incorporated and headquartered in Switzerland.
Summary of the business section of BeOne Medicines's latest annual report, written by StockData.
Company profile
Company
- Legal name
- BeOne Medicines Ltd.
- Founded
- 2010
- Headquarters
- Basel, Switzerland
- Address
- C/O Beone Medicines I Gmbh, Aeschengraben 27, 21st Floor 4051
- Phone
- 41-616851900
- Website
- beonemedicines.com
- Employees
- 12,000, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Fiscal year ends
- December 31
- Auditor
- Ernst& Young LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- ONC
- Other tickers
- BEIGF
- Former tickers
- BGNE until Jan 8, 2025
- Exchange
- Nasdaq
- IPO date
- Feb 3, 2016
- Shares outstanding
- 1.48B, Jul 31, 2026
- Public float
- $14.70B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1651308
- CUSIP
- 07725L102
- ISIN
- US07725L1026
- FIGI
- BBG00B6WF7T5
- Share class FIGI
- BBG00B6WF7V2
- LEI
- 549300JFUK6FRD5MH739
- EIN
- 98-1209416
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| John Oyler | Chief Executive Officer, Director | 7,815,448 |
| Titus B. Ball | Principal Accounting Officer | 0 |
| Chan Henry Lee | SVP, General Counsel | 0 |
| Xiaobin Wu | President and COO | 4,000 |
| Aaron Rosenberg | Chief Financial Officer | 0 |
| Lai Wang | President, Global Head of R&D | 601,965 |
| Xiaodong Wang | Director | 4,586,980 |
| Bros. Advisors Lp Baker | Director | 922,957 |
| Brothers Life Sciences LP Baker | Director | 8,229,958 |
| Felix Baker | Director | 997,946 |
| Bros. Advisors (GP) LLC Baker | Director | 730,643 |
| 667, L.P. | Director | 10,803,789 |
| Julian Baker | Director | 10,734,144 |
| Elizabeth Fisher Mooney | Director | 18,980 |
| Margaret Dugan | Director | 73,164 |
| Anthony C. Hooper | Director | 83,720 |
| Shalini Sharp | Director | 38,116 |
| Olivier Brandicourt | Director | 46,306 |
| Alessandro Riva | Director | 73,164 |
| Charles Lazelle Sawyers | Director | 1,946 |
| Qingqing Yi | Director | 0 |
| Corazon (Corsee) D. Sanders | Director | 0 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $17.94M | $60.67M | $10.46M | $118 | $125 |
| FY2024 | $20.84M | $14.97M | $7.94M | $71 | $93 |
| FY2023 | $18.93M | $11.43M | $7.11M | $70 | $94 |
| FY2022 | $18.05M | $11.22M | $6.36M | $85 | $90 |
| FY2021 | $16.75M | $22.88M | $5.14M | $105 | $100 |
| FY2020 | $14.41M | $40.75M | $5.18M | $156 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| John V. Oyler Co-Founder, Chairman and Chief Executive Officer | $1.13M | $11.25M | $3.75M | $1.68M | $133.83K | $17.94M | -14% |
| Aaron Rosenberg Chief Financial Officer | $660.00K | $3.87M | $1.29M | $586.08K | $21.00K | $6.43M | +5% |
| Dr. Xiaobin Wu President and Chief Operating Officer | $862.41K | $7.50M | $2.50M | $957.28K | $210.00K | $12.03M | +8% |
| Dr. Lai Wang President, Global Head of Research and Development | $659.49K | $15.25M | $1.75M | $585.63K | $74.70K | $18.32M | +147% |
| Chan Lee Senior Vice President, General Counsel and Corporate Secretary | $654.00K | $2.85M | $949.88K | $580.75K | $21.00K | $5.06M | +8% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Feb 3, 2016
- Offer price
- $24.00
- Securities offered
- 6,600,000
- Gross proceeds
- $158.40M
- Exchange
- Nasdaq
- First trading day
- Feb 3, 2016
- First-day close
- $28.32+18.0%
- Lock-up ends (est.)
- Aug 1, 2016
“The initial public offering price is $24.00 per ADS.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 27, 2025 | Name change | Name changed from BeiGene, Ltd. to BeOne Medicines Ltd. |
| Aug 7, 2024 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Mar 25, 2022 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jun 12, 2017 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jun 5, 2017 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Feb 3, 2016 | IPO | Initial public offering priced (424B4 prospectus) |
| Jan 29, 2016 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?